Back to Atlas
APotentially durableStandard research/education caution
CMP-0012
Discontinued investigational
ACE-083
Ergogenic / Myostatin
Localized skeletal muscle hypertrophy
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Fusion protein
- Primary mechanism
- Localized follistatin-derived ligand trap
- Primary market use
- Muscle wasting
Pharmacology
- Molecular weight (Da)
- ~70,000
- Oral bioavailability
- N/A
- Half-life
- ~8-12 d
- Route tags
- Route-dependent / verify
- Evidence level
- Human/Clinical
- Clinical status
- Discontinued investigational
- Value-for-money score
- 4 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Local structural hypertrophy candidate